MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Biomaterials (Orthopedic: Synthetic Bone, Cartilage & Skin Substitutes)
Mesoblast Limited (NASDAQ: MESO)*
Organization & Developments: Mesoblast
Parents
Mesoblast Limited (NASDAQ: MESO)*
Children
*Agreement Provides Cephalon with Global Rights in Three Treatment Areas to Products Derived from Mesoblast's Innovative Adult Mesenchymal Precursor Stem Cell Technology
*Australian biotechnology company committed to the development of novel treatments for orthopaedic conditions
*Including the commercialisation of unique adult stem cells to regenerate and repair bone and cartilage.
*Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult MPCs.
*Strategic alliance to develop and commercialize novel adult Mesenchymal Precursor Stem Cell (MPC) therapeutics for degenerative conditions of the cardiovascular and central nervous systems.
*The alliance also extends to products for augmenting hematopoietic stem cell transplantation in cancer patients.
*These conditions include Congestive Heart Failure, Acute Myocardial Infarction, Parkinson's Disease, and Alzheimer's Disease.
2018: Mesoblast: Pushing The Cell Therapy Treatment For An Unmet Medical Need For Children - Mesoblast (NASDAQ:MESO)
2019: Mesoblast: Investment Case_seekingalpha.com
2020: Mesoblast Before The PDUFA
2020: Mesoblast craters as Novartis-backed COVID-19 drug flunks trial
2020: Mesoblast Receives Complete Response Letter From the FDA for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children Australian Stock Exchange:MSB.AX
2020: Novartis bags Mesoblast's stem cell therapy for ARDS, including in Covid-19, in a deal worth up to $1.2B+
2023: Mesoblast Has A Strong Upside Potential_ seekingalpha.com
2024: Mesoblast After Approval: Stock Is Buoyant Now, But Unpredictable Overall
2024: Mesoblast Finally Gets Its Approval In GVHD: Where Now?_seekingalpha.com
2024: Mesoblast Limited: Back From The Dead
2024: Mesoblast Wins First Mesenchymal Stromal Cell Therapy FDA Approval for GVHD
2025: Mesoblast: A Cautionary Hold On Regenerative Medicine's Risky Edge (Upgrade)
2025: Mesoblast: Ryoncil Approval Overshadowed By Commercial Hurdles
Jumps
*Key People: Mesoblast
Finance & Acquisitions: Mesoblast (MESO)